Project Grant R01NS046006

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $356,174 to The Regents of the University of California, San Francisco (UCSF) to conduct in vivo testing of structure-based vaccine candidates targeting Alzheimer's disease. The goal is to determine the efficacy of an active immunization strategy in preserving cognitive and neural function by slowing the formation of amyloid-beta or tau protein aggregation in the brain. The research will use...

The National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), awarded a $1,684,689 project grant to Weill Medical College of Cornell University to study the role of microglial lysosomes in the degradation of amyloid-beta, a key pathological feature of Alzheimer's disease. The 3-year project aims to characterize the process of "digestive exophagy" used by microglia to limit the expansion of amyloid-beta plaques, as well as explore the effects of genetic...

This three-year, $8.29 million project grant from the National Institutes of Health National Institute on Aging will support the development of full human gene replacement mouse models of Alzheimer's disease. Funded under the Aging Research program (CFDA 93.866), the Regents of the University of Minnesota will generate mouse lines with replacement of key Alzheimer's-related genes, including APP, PSEN1, PSEN2, MAPT, APOE, TREM2, MS4A, and INPP5D, with their full human orthologues. Control lines...

The National Institute on Aging (NIA) awarded a $486,750 Project Grant under the Aging Research federal grant program (CFDA 93.866) to The Jackson Laboratory in Bar Harbor, Maine. The goal of this 2-year project is to investigate the impact of age-related clonal hematopoiesis mutations in peripheral immune cells on the etiology and progression of Alzheimer's disease using mouse models. The research aims to establish whether functional changes in peripheral immune cells influence the onset and...

The National Institute on Aging (NIA) awarded a $1,994,202 Project Grant under CFDA 93.866 - Aging Research to Mayo Clinic Jacksonville (A Nonprofit Corporation) to research a new microglial therapy candidate for Alzheimer's disease (AD) that could prevent cognitive decline. The grant aims to target the tumor susceptibility gene 101 (TSG101) in microglia to manipulate extracellular vesicle secretion and mitigate tau pathology development. The research will be conducted in three phases: targeting...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $455,009 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a novel [18F]-labeled amphiphilic PET probe that can cross the blood-brain barrier and track CD206+ microglia/macrophages in Alzheimer's disease. The goal is to create a non-invasive imaging method to detect anti-inflammatory M2-like microglia and macrophages, which play a key role in...

This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...

This $810,596 Project Grant award from the National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), aims to develop a novel chimeric antigen receptor (CAR)-engineered macrophage (CAR-MI) therapy for Alzheimer's disease (AD). The goal is to create "off-the-shelf" human induced pluripotent stem cell (HIPSC)-derived CAR-MIs that can effectively target and clear misfolded proteins associated with AD pathology, while also modulating neuroinflammation....

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $374,000.00 to the University of California, Los Angeles (UCLA) to develop and evaluate a novel hematopoietic stem cell-based chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease (AD). The key objectives are to: 1) Optimize an AB-targeting CAR-macrophage (CAR-M) therapy for in vitro efficacy against AB aggregates and reducing neuroinflammation, and 2) Investigate the safety...

The University of Virginia (UVA) has been awarded a $444,125 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to investigate the impact of reduced phagocytosis (cell debris clearance) on Alzheimer's disease (AD) pathology. The project aims to test the hypothesis that decreased efferocytosis (clearance of apoptotic cells) can alleviate amyloid-beta induced pathology by enhancing debris processing and degradation in microglia. Specific...